[1]
Hill AJ, Stone DE, Elliott JP, Gerkin RD, Ingersoll M, Cook CR. Management of Nephrotic Syndrome in the Pregnant Patient. The Journal of reproductive medicine. 2016 Nov-Dec:61(11-12):557-61
[PubMed PMID: 30226702]
[2]
Raina R, Krishnappa V. An update on LDL apheresis for nephrotic syndrome. Pediatric nephrology (Berlin, Germany). 2019 Oct:34(10):1655-1669. doi: 10.1007/s00467-018-4061-9. Epub 2018 Sep 14
[PubMed PMID: 30218191]
[3]
Dumas De La Roque C, Prezelin-Reydit M, Vermorel A, Lepreux S, Deminière C, Combe C, Rigothier C. Idiopathic Nephrotic Syndrome: Characteristics and Identification of Prognostic Factors. Journal of clinical medicine. 2018 Sep 9:7(9):. doi: 10.3390/jcm7090265. Epub 2018 Sep 9
[PubMed PMID: 30205613]
[5]
Rood IM, Deegens JKJ, Lugtenberg D, Bongers EMHF, Wetzels JFM. Nephrotic Syndrome With Mutations in NPHS2: The Role of R229Q and Implications for Genetic Counseling. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2019 Mar:73(3):400-403. doi: 10.1053/j.ajkd.2018.06.034. Epub 2018 Sep 18
[PubMed PMID: 30241959]
[6]
Dumas De La Roque C, Combe C, Rigothier C. [Up to date of pathophysiology mechanism of idiopathic nephrotic syndromes: Minimal change disease and focal and segmental glomerulosclerosis]. Nephrologie & therapeutique. 2018 Dec:14(7):501-506. doi: 10.1016/j.nephro.2018.06.001. Epub 2018 Aug 24
[PubMed PMID: 30150079]
[7]
Lewis G, Maxwell AP. Timely diagnosis and treatment essential in glomerulonephritis. The Practitioner. 2015 Feb:259(1779):13-7, 2
[PubMed PMID: 25816500]
[8]
Mérida E, Praga M. NSAIDs and Nephrotic Syndrome. Clinical journal of the American Society of Nephrology : CJASN. 2019 Sep 6:14(9):1280-1282. doi: 10.2215/CJN.08090719. Epub 2019 Aug 15
[PubMed PMID: 31416889]
[9]
Nagahama K, Matsushita H, Hara M, Ubara Y, Hara S, Yamada A. Bucillamine induces membranous glomerulonephritis. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2002 Apr:39(4):706-12
[PubMed PMID: 11920335]
[10]
Jia N, Cormack FC, Xie B, Shiue Z, Najafian B, Gralow JR. Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature. BMC cancer. 2015 Jul 22:15():535. doi: 10.1186/s12885-015-1536-y. Epub 2015 Jul 22
[PubMed PMID: 26197890]
Level 3 (low-level) evidence
[11]
Kayar Y, Bayram Kayar N, Alpay N, Hamdard J, Ekinci I, Emegil S, Bag Soydas R, Baysal B. Interferon Induced Focal Segmental Glomerulosclerosis. Case reports in nephrology. 2016:2016():6967378
[PubMed PMID: 27847659]
Level 3 (low-level) evidence
[12]
McCloskey O, Maxwell AP. Diagnosis and management of nephrotic syndrome. The Practitioner. 2017 Feb:261(1801):11-5
[PubMed PMID: 29020719]
[13]
Wong W. Idiopathic nephrotic syndrome in New Zealand children, demographic, clinical features, initial management and outcome after twelve-month follow-up: results of a three-year national surveillance study. Journal of paediatrics and child health. 2007 May:43(5):337-41
[PubMed PMID: 17489822]
[14]
Kumar J, Gulati S, Sharma AP, Sharma RK, Gupta RK. Histopathological spectrum of childhood nephrotic syndrome in Indian children. Pediatric nephrology (Berlin, Germany). 2003 Jul:18(7):657-60
[PubMed PMID: 12743793]
[15]
Ozkaya N, Cakar N, Ekim M, Kara N, Akkök N, Yalçinkaya F. Primary nephrotic syndrome during childhood in Turkey. Pediatrics international : official journal of the Japan Pediatric Society. 2004 Aug:46(4):436-8
[PubMed PMID: 15310309]
[16]
Kazi JI, Mubarak M. Pattern of glomerulonephritides in adult nephrotic patients--report from SIUT. JPMA. The Journal of the Pakistan Medical Association. 2007 Nov:57(11):574
[PubMed PMID: 18062530]
[18]
Doe JY, Funk M, Mengel M, Doehring E, Ehrich JH. Nephrotic syndrome in African children: lack of evidence for 'tropical nephrotic syndrome'? Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2006 Mar:21(3):672-6
[PubMed PMID: 16326742]
[19]
Pakasa NM, Sumaili EK. The nephrotic syndrome in the Democratic Republic of Congo. The New England journal of medicine. 2006 Mar 9:354(10):1085-6
[PubMed PMID: 16525148]
[20]
Sumaili EK, Krzesinski JM, Zinga CV, Cohen EP, Delanaye P, Munyanga SM, Nseka NM. Prevalence of chronic kidney disease in Kinshasa: results of a pilot study from the Democratic Republic of Congo. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2009 Jan:24(1):117-22. doi: 10.1093/ndt/gfn469. Epub 2008 Aug 20
[PubMed PMID: 18715963]
Level 3 (low-level) evidence
[21]
Fine DM, Wasser WG, Estrella MM, Atta MG, Kuperman M, Shemer R, Rajasekaran A, Tzur S, Racusen LC, Skorecki K. APOL1 risk variants predict histopathology and progression to ESRD in HIV-related kidney disease. Journal of the American Society of Nephrology : JASN. 2012 Feb:23(2):343-50. doi: 10.1681/ASN.2011060562. Epub 2011 Dec 1
[PubMed PMID: 22135313]
[22]
Bonilla-Felix M, Parra C, Dajani T, Ferris M, Swinford RD, Portman RJ, Verani R. Changing patterns in the histopathology of idiopathic nephrotic syndrome in children. Kidney international. 1999 May:55(5):1885-90
[PubMed PMID: 10231451]
[23]
Lefaucheur C, Stengel B, Nochy D, Martel P, Hill GS, Jacquot C, Rossert J, GN-PROGRESS Study Group. Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association. Kidney international. 2006 Oct:70(8):1510-7
[PubMed PMID: 16941021]
[24]
Vukojevic K, Raguz F, Saraga M, Filipovic N, Bocina I, Kero D, Glavina Durdov M, Martinovic V, Saraga-Babic M. Glomeruli from patients with nephrin mutations show increased number of ciliated and poorly differentiated podocytes. Acta histochemica. 2018 Nov:120(8):748-756. doi: 10.1016/j.acthis.2018.08.015. Epub 2018 Sep 5
[PubMed PMID: 30193978]
[25]
Esprit DH, Amin MS, Koratala A. Uncommon things to note about a common cause of nephrotic syndrome. Clinical case reports. 2018 Aug:6(8):1645-1646. doi: 10.1002/ccr3.1676. Epub 2018 Jul 1
[PubMed PMID: 30147928]
Level 3 (low-level) evidence
[26]
Brkovic V, Milinkovic M, Kravljaca M, Lausevic M, Basta-Jovanovic G, Marković-Lipkovski J, Naumovic R. Does the pathohistological pattern of renal biopsy change during time? Pathology, research and practice. 2018 Oct:214(10):1632-1637. doi: 10.1016/j.prp.2018.07.027. Epub 2018 Aug 10
[PubMed PMID: 30139556]
[27]
Haraldsson B, Nyström J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiological reviews. 2008 Apr:88(2):451-87. doi: 10.1152/physrev.00055.2006. Epub
[PubMed PMID: 18391170]
[28]
Bockenhauer D. Over- or underfill: not all nephrotic states are created equal. Pediatric nephrology (Berlin, Germany). 2013 Aug:28(8):1153-6. doi: 10.1007/s00467-013-2435-6. Epub 2013 Mar 26
[PubMed PMID: 23529637]
[29]
Hamm LL, Batuman V. Edema in the nephrotic syndrome: new aspect of an old enigma. Journal of the American Society of Nephrology : JASN. 2003 Dec:14(12):3288-9
[PubMed PMID: 14638928]
[30]
Rostoker G, Behar A, Lagrue G. Vascular hyperpermeability in nephrotic edema. Nephron. 2000 Jul:85(3):194-200
[PubMed PMID: 10867533]
[31]
Vivarelli M, Massella L, Ruggiero B, Emma F. Minimal Change Disease. Clinical journal of the American Society of Nephrology : CJASN. 2017 Feb 7:12(2):332-345. doi: 10.2215/CJN.05000516. Epub 2016 Dec 9
[PubMed PMID: 27940460]
[32]
Alchi B, Jayne D. Membranoproliferative glomerulonephritis. Pediatric nephrology (Berlin, Germany). 2010 Aug:25(8):1409-18. doi: 10.1007/s00467-009-1322-7. Epub 2009 Nov 12
[PubMed PMID: 19908070]
[33]
Couser WG. Primary Membranous Nephropathy. Clinical journal of the American Society of Nephrology : CJASN. 2017 Jun 7:12(6):983-997. doi: 10.2215/CJN.11761116. Epub 2017 May 26
[PubMed PMID: 28550082]
[34]
Dantas M, Barros Silva GE, Moysés-Neto M. Foamy urine in nephrotic syndrome. Clinical kidney journal. 2013 Jun:6(3):341. doi: 10.1093/ckj/sft018. Epub 2013 Apr 11
[PubMed PMID: 26064498]
[35]
Khanna R. Clinical presentation & management of glomerular diseases: hematuria, nephritic & nephrotic syndrome. Missouri medicine. 2011 Jan-Feb:108(1):33-6
[PubMed PMID: 21462608]
[36]
Deshpande NS, Tewari R, Badwal S, Mendonca S, Bharadwaj R. Evaluation of cases of membranoproliferative glomerulonephritis according to newer classification: A retrospective record-based study. Medical journal, Armed Forces India. 2018 Jul:74(3):264-267. doi: 10.1016/j.mjafi.2017.01.008. Epub 2017 Feb 16
[PubMed PMID: 30093770]
Level 2 (mid-level) evidence
[37]
Noone DG, Iijima K, Parekh R. Idiopathic nephrotic syndrome in children. Lancet (London, England). 2018 Jul 7:392(10141):61-74. doi: 10.1016/S0140-6736(18)30536-1. Epub 2018 Jun 14
[PubMed PMID: 29910038]
[38]
Sultana MN, Majumder B, Rahman MJ, Moniruzzaman AM, Suja AM, Ali ME, Sarker ZH, Nabi SN, Mostakim MA. Dipstick Method versus Spot Urinary Protein Creatinine Ratio for Evaluation of Massive Proteinuria in Childhood Nephrotic Syndrome. Mymensingh medical journal : MMJ. 2018 Apr:27(2):369-374
[PubMed PMID: 29769504]
[39]
Russo LM, Bakris GL, Comper WD. Renal handling of albumin: a critical review of basic concepts and perspective. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2002 May:39(5):899-919
[PubMed PMID: 11979334]
Level 3 (low-level) evidence
[40]
Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. The New England journal of medicine. 2009 Jul 2:361(1):11-21. doi: 10.1056/NEJMoa0810457. Epub
[PubMed PMID: 19571279]
[41]
Hofstra JM, Beck LH Jr, Beck DM, Wetzels JF, Salant DJ. Anti-phospholipase A₂ receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clinical journal of the American Society of Nephrology : CJASN. 2011 Jun:6(6):1286-91. doi: 10.2215/CJN.07210810. Epub 2011 Apr 7
[PubMed PMID: 21474589]
[42]
Cambier A, Rabant M, Peuchmaur M, Hertig A, Deschenes G, Couchoud C, Kolko A, Salomon R, Hogan J, Robert T. Immunosuppressive Treatment in Children With IgA Nephropathy and the Clinical Value of Podocytopathic Features. Kidney international reports. 2018 Jul:3(4):916-925. doi: 10.1016/j.ekir.2018.03.013. Epub 2018 Mar 29
[PubMed PMID: 29988999]
[43]
Bérody S, Heidet L, Gribouval O, Harambat J, Niaudet P, Baudouin V, Bacchetta J, Boudaillez B, Dehennault M, de Parscau L, Dunand O, Flodrops H, Fila M, Garnier A, Louillet F, Macher MA, May A, Merieau E, Monceaux F, Pietrement C, Rousset-Rouvière C, Roussey G, Taque S, Tenenbaum J, Ulinski T, Vieux R, Zaloszyc A, Morinière V, Salomon R, Boyer O. Treatment and outcome of congenital nephrotic syndrome. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2019 Mar 1:34(3):458-467. doi: 10.1093/ndt/gfy015. Epub
[PubMed PMID: 29474669]
[44]
Trivin-Avillach C, Thervet É. [Immunizations for patients with kidney disease]. Nephrologie & therapeutique. 2019 Jul:15(4):233-240. doi: 10.1016/j.nephro.2017.11.007. Epub 2018 Jun 19
[PubMed PMID: 29887267]
[45]
Kallash M, Smoyer WE, Mahan JD. Rituximab Use in the Management of Childhood Nephrotic Syndrome. Frontiers in pediatrics. 2019:7():178. doi: 10.3389/fped.2019.00178. Epub 2019 May 10
[PubMed PMID: 31134169]
[46]
Mühlig AK, Lee JY, Kemper MJ, Kronbichler A, Yang JW, Lee JM, Shin JI, Oh J. Levamisole in Children with Idiopathic Nephrotic Syndrome: Clinical Efficacy and Pathophysiological Aspects. Journal of clinical medicine. 2019 Jun 16:8(6):. doi: 10.3390/jcm8060860. Epub 2019 Jun 16
[PubMed PMID: 31208104]
[47]
Sinha A, Puraswani M, Kalaivani M, Goyal P, Hari P, Bagga A. Efficacy and safety of mycophenolate mofetil versus levamisole in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial. Kidney international. 2019 Jan:95(1):210-218. doi: 10.1016/j.kint.2018.08.039. Epub 2018 Nov 26
[PubMed PMID: 30497684]
Level 1 (high-level) evidence
[48]
Okutsu M, Kamei K, Sato M, Kanamori T, Nishi K, Ishiwa S, Ogura M, Sako M, Ito S, Ishikura K. Prophylactic rituximab administration in children with complicated nephrotic syndrome. Pediatric nephrology (Berlin, Germany). 2021 Mar:36(3):611-619. doi: 10.1007/s00467-020-04771-5. Epub 2020 Sep 30
[PubMed PMID: 32995922]
[49]
Papa R, Lachmann HJ. Secondary, AA, Amyloidosis. Rheumatic diseases clinics of North America. 2018 Nov:44(4):585-603. doi: 10.1016/j.rdc.2018.06.004. Epub 2018 Sep 7
[PubMed PMID: 30274625]
[50]
Ajayan P, Krishnamurthy S, Biswal N, Mandal J. Clinical spectrum and predictive risk factors of major infections in hospitalized children with nephrotic syndrome. Indian pediatrics. 2013 Aug:50(8):779-81
[PubMed PMID: 23502669]
[51]
Lane ER, Hsu EK, Murray KF. Management of ascites in children. Expert review of gastroenterology & hepatology. 2015:9(10):1281-92. doi: 10.1586/17474124.2015.1083419. Epub 2015 Sep 1
[PubMed PMID: 26325252]
[52]
Lin R, McDonald G, Jolly T, Batten A, Chacko B. A Systematic Review of Prophylactic Anticoagulation in Nephrotic Syndrome. Kidney international reports. 2020 Apr:5(4):435-447. doi: 10.1016/j.ekir.2019.12.001. Epub 2019 Dec 12
[PubMed PMID: 32274450]
Level 1 (high-level) evidence
[53]
Kodner C. Diagnosis and Management of Nephrotic Syndrome in Adults. American family physician. 2016 Mar 15:93(6):479-85
[PubMed PMID: 26977832]
[54]
Appel GB. Improved outcomes in nephrotic syndrome. Cleveland Clinic journal of medicine. 2006 Feb:73(2):161-7
[PubMed PMID: 16478040]
[55]
Goel RM, Johnston EL, Patel KV, Wong T. Budd-Chiari syndrome: investigation, treatment and outcomes. Postgraduate medical journal. 2015 Dec:91(1082):692-7. doi: 10.1136/postgradmedj-2015-133402. Epub 2015 Oct 22
[PubMed PMID: 26494427]
[56]
Fogo AB. Causes and pathogenesis of focal segmental glomerulosclerosis. Nature reviews. Nephrology. 2015 Feb:11(2):76-87. doi: 10.1038/nrneph.2014.216. Epub 2014 Dec 2
[PubMed PMID: 25447132]
[57]
Tang X, Xu F, Chen DM, Zeng CH, Liu ZH. The clinical course and long-term outcome of primary focal segmental glomerulosclerosis in Chinese adults. Clinical nephrology. 2013 Aug:80(2):130-9. doi: 10.5414/CN107607. Epub
[PubMed PMID: 23380386]
[58]
Vaziri ND. HDL abnormalities in nephrotic syndrome and chronic kidney disease. Nature reviews. Nephrology. 2016 Jan:12(1):37-47. doi: 10.1038/nrneph.2015.180. Epub 2015 Nov 16
[PubMed PMID: 26568191]
[59]
Jackson AA. Albumin in nephrotic syndrome and oedematous malnutrition. Paediatrics and international child health. 2015 May:35(2):77-80. doi: 10.1179/2046904715Z.000000000249. Epub
[PubMed PMID: 25975277]
[60]
Kerlin BA, Ayoob R, Smoyer WE. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clinical journal of the American Society of Nephrology : CJASN. 2012 Mar:7(3):513-20. doi: 10.2215/CJN.10131011. Epub 2012 Feb 16
[PubMed PMID: 22344511]
[61]
Choudhary S, Agarwal I, Seshadri MS. Calcium and vitamin D for osteoprotection in children with new-onset nephrotic syndrome treated with steroids: a prospective, randomized, controlled, interventional study. Pediatric nephrology (Berlin, Germany). 2014 Jun:29(6):1025-32. doi: 10.1007/s00467-013-2720-4. Epub 2014 Jan 12
[PubMed PMID: 24414607]
Level 1 (high-level) evidence
[62]
Fenton A, Smith SW, Hewins P. Adult minimal-change disease: observational data from a UK centre on patient characteristics, therapies, and outcomes. BMC nephrology. 2018 Aug 16:19(1):207. doi: 10.1186/s12882-018-0999-x. Epub 2018 Aug 16
[PubMed PMID: 30115013]
[63]
Bomback AS, Fervenza FC. Membranous Nephropathy: Approaches to Treatment. American journal of nephrology. 2018:47 Suppl 1():30-42. doi: 10.1159/000481635. Epub 2018 May 31
[PubMed PMID: 29852477]
[64]
Carpenter SL, Goldman J, Sherman AK, Selewski DT, Kallash M, Tran CL, Seamon M, Katsoufis C, Ashoor I, Hernandez J, Supe-Markovina K, D'alessandri-Silva C, DeJesus-Gonzalez N, Vasylyeva TL, Formeck C, Woll C, Gbadegesin R, Geier P, Devarajan P, Smoyer WE, Kerlin BA, Rheault MN. Association of infections and venous thromboembolism in hospitalized children with nephrotic syndrome. Pediatric nephrology (Berlin, Germany). 2019 Feb:34(2):261-267. doi: 10.1007/s00467-018-4072-6. Epub 2018 Sep 7
[PubMed PMID: 30194664]
[65]
Katsuno T, Masuda T, Saito S, Kato N, Ishimoto T, Kato S, Kosugi T, Tsuboi N, Kitamura H, Tsuzuki T, Ito Y, Maruyama S. Therapeutic efficacy of rituximab for the management of adult-onset steroid-dependent nephrotic syndrome: a retrospective study. Clinical and experimental nephrology. 2019 Feb:23(2):207-214. doi: 10.1007/s10157-018-1630-y. Epub 2018 Aug 18
[PubMed PMID: 30121802]
Level 2 (mid-level) evidence
[66]
Sibley M, Roshan A, Alshami A, Catapang M, Jöbsis JJ, Kwok T, Polderman N, Sibley J, Matsell DG, Mammen C, Pediatric Nephrology Clinical Pathway Development Team. Induction prednisone dosing for childhood nephrotic syndrome: how low should we go? Pediatric nephrology (Berlin, Germany). 2018 Sep:33(9):1539-1545. doi: 10.1007/s00467-018-3975-6. Epub 2018 May 22
[PubMed PMID: 29789934]